Mon. 13 May 2024, 8:38am ET
Benzinga
Biotech, News, Events, General
- Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of the patient journey
- Improved survival demonstrated with both Iomab-B and Actimab-A in patients with high-risk acute myeloid leukemia including those with a TP53 mutation and prior venetoclax treatment
- Novel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor indications